Article Details
Retrieved on: 2024-05-24 17:00:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the use of medical physics and biotechnology, overseen by Singapore's A*STAR, in progressing a Phase 1 trial for EBC-129, an anti-cancer drug. This development has shown promise in treating hard-to-treat cancers including pancreatic cancer.
Article found on: www.news-medical.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here